OpinionNewer IL-17 inhibitors make their case in phase 3 nonradiographic axial spondyloarthritis trialsAuthor:Nigil Haroon, MD, PhDPublish date: November 21, 2019There appears to be very little to favor either ixekizumab or secukinumab over the other.Read More
